Exact Sciences Corporation(EXAS)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Exact Sciences is demonstrating significant top-line momentum with 23.1% year-over-year revenue growth in 2025Q4, yet the firm remains challenged by a persistent inability to achieve operating leverage as SG&A expenses continue to outpace gross profit.
• While the company has successfully transitioned to positive free cash flow of $120.4 million in the most recent quarter, the reliance on $2.5 billion in total debt and a $4.7 billion accumulated deficit necessitates a cautious outlook.
• Investors should monitor whether the firm can sustain this cash-generating inflection point without further diluting shareholder equity or increasing its already substantial $2.4 billion goodwill-heavy asset base.